TY - JOUR
T1 - Eliminating Hepatitis C Virus among Human Immunodeficiency Virus-Infected Men Who Have Sex with Men in Berlin
T2 - A Modeling Analysis
AU - Martin, Natasha K.
AU - Jansen, Klaus
AU - An Der Heiden, Matthias
AU - Boesecke, Christoph
AU - Boyd, Anders
AU - Schewe, Knud
AU - Baumgarten, Axel
AU - Lutz, Thomas
AU - Christensen, Stefan
AU - Thielen, Alexander
AU - Mauss, Stefan
AU - Rockstroh, Jürgen K.
AU - Skaathun, Britt
AU - Ingiliz, Patrick
N1 - Funding Information:
Potential conflicts of interest. N. K. M. has received unrestricted research grants and honoraria from Gilead and Merck. C. B. reports personal fees from AbbVie, Gilead, Johnson & Johnson, Merck Sharp & Dohme (MSD), and ViiV and grants from DZIF (German Center for Infection Research), Deutsche Leberstiftung, and Hector Stiftung. A. Baumgarten reports grants from Zentrum für Infektiologie Berlin Prenzlauer Berg and personal fees from AbbVie, Gilead, Janssen, Sanofi, MSD, and ViiV. T. L. reports grants from AbbVie, Gilead Sciences, ViiV, Janssen-Cilag, MSD, Deutsche Leberstiftung, and DAGNÄ for scientific work. S. C. reports personal fees from Gilead, AbbVie, ViiV, MSD, and Indivior. S. M. reports personal fees from AbbVie, Gilead, and MSD. J. K. R. reports personal fees from Abivax, AbbVie, Gilead, Janssen, Merck, and ViiV, outside the submitted work. P. I. has received unrestricted research grants from Gilead and speaker fees from Gilead, AbbVie, ViiV, MSD, and Bristol-Myers Squibb. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Funding Information:
Financial support. This work was supported by Gilead Sciences (unrestricted research grant funding to N. K. M.), the National Institute for Drug Abuse, NIH (grant R01 DA037773 to N. K. M.), and the University of California, San Diego, Center for AIDS Research, an NIH-funded program (grant P30 AI036214 to N. K. M.).
Publisher Copyright:
© 2019 The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: [email protected].
PY - 2019/10/8
Y1 - 2019/10/8
N2 - Background: Despite high hepatitis C virus (HCV) treatment rates, HCV incidence among human immunodeficiency virus (HIV)-infected men who have sex with men (HIV-infected MSM) in Germany rose before HCV direct-acting antivirals (DAAs). We model what intervention can achieve the World Health Organization (WHO) elimination target of an 80% reduction in HCV incidence by 2030 among HIV-infected MSM in Berlin. Methods: An HCV transmission model among HIV-diagnosed MSM was calibrated to Berlin (rising HCV incidence and high rates of HCV testing and treatment). We modeled the HCV incidence among HIV-diagnosed MSM in Berlin until 2030 (relative to 2015 WHO baseline) under scenarios of DAA scale-up with or without behavior change (among HIV-diagnosed MSM and/or all MSM). Results: Continuing current treatment rates will marginally reduce the HCV incidence among HIV-diagnosed MSM in Berlin by 2030. Scaling up DAA treatment rates, beginning in 2018, to 100% of newly diagnosed HCV infections within 3 months of diagnosis and 25% each year of previously diagnosed and untreated HCV infections could reduce the HCV incidence by 61% (95% confidence interval, 55.4%-66.7%) by 2030. The WHO target would likely be achieved by combining DAA scale-up with a 40% reduction in HCV transmission among HIV-diagnosed MSM and a 20% reduction among HIV-undiagnosed or HIV-uninfected MSM. Discussion: HCV elimination among HIV-infected MSM in Berlin likely requires combining DAA scale-up with moderately effective behavioral interventions to reduce risk among all MSM.
AB - Background: Despite high hepatitis C virus (HCV) treatment rates, HCV incidence among human immunodeficiency virus (HIV)-infected men who have sex with men (HIV-infected MSM) in Germany rose before HCV direct-acting antivirals (DAAs). We model what intervention can achieve the World Health Organization (WHO) elimination target of an 80% reduction in HCV incidence by 2030 among HIV-infected MSM in Berlin. Methods: An HCV transmission model among HIV-diagnosed MSM was calibrated to Berlin (rising HCV incidence and high rates of HCV testing and treatment). We modeled the HCV incidence among HIV-diagnosed MSM in Berlin until 2030 (relative to 2015 WHO baseline) under scenarios of DAA scale-up with or without behavior change (among HIV-diagnosed MSM and/or all MSM). Results: Continuing current treatment rates will marginally reduce the HCV incidence among HIV-diagnosed MSM in Berlin by 2030. Scaling up DAA treatment rates, beginning in 2018, to 100% of newly diagnosed HCV infections within 3 months of diagnosis and 25% each year of previously diagnosed and untreated HCV infections could reduce the HCV incidence by 61% (95% confidence interval, 55.4%-66.7%) by 2030. The WHO target would likely be achieved by combining DAA scale-up with a 40% reduction in HCV transmission among HIV-diagnosed MSM and a 20% reduction among HIV-undiagnosed or HIV-uninfected MSM. Discussion: HCV elimination among HIV-infected MSM in Berlin likely requires combining DAA scale-up with moderately effective behavioral interventions to reduce risk among all MSM.
KW - elimination
KW - HCV
KW - hepatitis C virus
KW - modeling
KW - prevention
UR - https://www.scopus.com/pages/publications/85073081055
U2 - 10.1093/infdis/jiz367
DO - 10.1093/infdis/jiz367
M3 - Article
C2 - 31301142
SN - 0022-1899
VL - 220
SP - 1635
EP - 1644
JO - Journal of infectious diseases
JF - Journal of infectious diseases
IS - 10
ER -
SDG 3 Good Health and Well-being